Results 1 to 10 of about 2,146 (159)

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab [PDF]

Annals of Clinical and Translational Neurology
Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG)
Guido Wabnitz, Frauke Stascheit, Andreas Meisel   +2 more
exaly   +3 more sources

Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study [PDF]

Annals of Hematology
Ravulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH.
Anna Paola Iori, Antonio De Vivo, Eros Di Bona, Giovanni Caocci, Francesca Fioritoni, Fabio Ciceri, Eloise Beggiato, Davide Rapezzi, Angela Amendola, Amalia Figuera, Carmine Selleri, Francesco Longu, Bruno Fattizzo, Alessandra Tucci, Alessandro Cignetti, Valeria Amico, Simona Sica, Elisabetta Metafuni, Simona Raso, Tiziana Anna Urbano, Luana Marano, Nicola Di Renzo, Pierangelo Spedini, Alessandro Rambaldi, Francesco Lanza, Cristina Clissa, Cristina Danesin, Maria Bruna Greve, Sergio Cabibbo, Alessandra Ori, Francesca Cassanelli, Federica Sottana, Benedetta Campolo, Giulia Gasparri, Fabio Carini, Wilma Barcellini   +35 more
doaj   +2 more sources

Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab

Kidney International Reports
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death.
Franz Schaefer, Larry Greenbaum, G Ariceta   +2 more
exaly   +3 more sources

Complement mediated thrombotic microangiopathy after liver transplantation in combination with a novel C6 variant of uncertain significance [PDF]

Frontiers in Immunology
Thrombotic microangiopathies (TMAs) encompass a spectrum of severe pathological conditions mostly characterized by hemolytic anemia, microvascular thrombosis with organ failure, and thrombocytopenia.
Nicola Sariye Pollmann, Lisa Hauptmann, Martin Busch, Lukas Pollmann, Andrea Tannapfel, Oliver Rohland, Aladdin Ali Deeb, Falk Rauchfuß, Utz Settmacher, Felix Dondorf   +9 more
doaj   +2 more sources

Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient [PDF]

Frontiers in Medicine
Thrombotic microangiopathy (TMA) after kidney transplantation presents a significant diagnostic and therapeutic challenge. Complement-mediated thrombotic microangiopathy (CM-TMA), caused by dysregulation of the alternative complement pathway, is ...
Michael Fink, Marion Pollheimer, Alexander Kirsch, Alexander R. Rosenkranz, Kathrin Eller, Max Schuller   +5 more
doaj   +2 more sources

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Kidney Medicine
Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes
Yoshitaka Miyakawa, Bradley Dixon, Katherine Garlo   +2 more
exaly   +3 more sources

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2019
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert Stern, Nathan Connell
exaly   +2 more sources

Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database [PDF]

Frontiers in Immunology
BackgroundRavulizumab is a long-acting C5 complement inhibitor that provides sustained suppression of the complement pathway. It is currently approved by the US Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis ...
Yue Zhou, Yutong Wu, Yingchao Su, Zhaoyou Meng   +3 more
doaj   +2 more sources

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study) [PDF]

Kidney Medicine
Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab, a complement C5 inhibitor (C5i), is approved for aHUS; however, published evidence in
Ramy Magdy Hanna, Shruti Chaturvedi, Moh-Lim Ong, Arpita Nag, Rui Song, Lynn Huynh, Jordan A. Burdeau, Mei Sheng Duh, Yan Wang   +8 more
doaj   +2 more sources

A case report on the effective and safe use of ravulizumab in atypical hemolytic uremic syndrome during pregnancy [PDF]

BMC Nephrology
Background Atypical hemolytic uremic Syndrome (aHUS), a form of thrombotic microangiopathy (TMA), had a poor prognosis until the development of complement C5-inhibiting monoclonal antibodies, eculizumab and ravulizumab.
Abdulaziz Alkhaldi, Mamoun Elawad, Sultan Al Dalbhi, Bandar Alquraini, Alanoud Alshannan   +4 more
doaj   +2 more sources